Skip to main content
Top
Published in: BMC Urology 1/2015

Open Access 01-12-2015 | Research article

Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer

Authors: Yan-Ru Zeng, Zhao-Dong Han, Cong Wang, Chao Cai, Ya-Qiang Huang, Hong-Wei Luo, Ze-Zhen Liu, Yang-Jia Zhuo, Qi-Shan Dai, Hai-Bo Zhao, Yu-Xiang Liang, Wei-De Zhong

Published in: BMC Urology | Issue 1/2015

Login to get access

Abstract

Background

The NIMA-related kinase 2 (NEK2) is a serine/threonine kinase that is involved in regulation of centrosome duplication and spindle assembly during mitosis. Dysregulation of these processes causes chromosome instability and aneuploidy, which are hallmark changes of many solid tumors. However, whether aberrant expression of NEK2 is associated with outcome of prostate cancer (PCa) patients remains to be determined.

Methods

Expression of NEK2 in human PCa cells and primary PCa tissues was assessed by quantitative RT-PCR. Expression of NEK2 in human PCa cells was depleted with siRNA. Effects of the depletion on cell proliferation, survival, and tumorigenicity were assessed both in vitro with cell cultures and in vivo with subcutaneous implantation of xenografts. In silico analyses of the online Taylor dataset were carried out to determine whether the expression level of NEK2 correlated with the clinicopathological characteristics of prostate cancer.

Results

Compared with benign human prostatic epithelial cells and tissues, the expression of NEK2 was elevated in human PCa cells and primary PCa tissues. Depleting NEK2 expression inhibited human PCa cell proliferation in vitro and xenograft growth in vivo. Expression level of NEK2 in PCa positively correlated with the Gleason score and pathologic stage of the patient.

Conclusion

The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa prognosis. Further validation with large sample pool is warrant.
Literature
2.
go back to reference Bornens M. Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol. 2002;14(1):25–34.CrossRefPubMed Bornens M. Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol. 2002;14(1):25–34.CrossRefPubMed
3.
go back to reference Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58(17):3974–85.PubMed Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58(17):3974–85.PubMed
4.
go back to reference Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A. 1998;95(6):2950–5.CrossRefPubMedPubMedCentral Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A. 1998;95(6):2950–5.CrossRefPubMedPubMedCentral
5.
go back to reference Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001;61(5):2212–9.PubMed Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001;61(5):2212–9.PubMed
6.
go back to reference Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2(1):21–32.CrossRefPubMed Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2(1):21–32.CrossRefPubMed
7.
go back to reference Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene. 2002;21(40):6184–94.CrossRefPubMed Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene. 2002;21(40):6184–94.CrossRefPubMed
8.
go back to reference Hames RS, Fry AM. Alternative splice variants of the human centrosome kinase Nek2 exhibit distinct patterns of expression in mitosis. Biochem J. 2002;361(Pt 1):77–85.CrossRefPubMedPubMedCentral Hames RS, Fry AM. Alternative splice variants of the human centrosome kinase Nek2 exhibit distinct patterns of expression in mitosis. Biochem J. 2002;361(Pt 1):77–85.CrossRefPubMedPubMedCentral
9.
go back to reference Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006;237(2):155–66.CrossRefPubMed Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006;237(2):155–66.CrossRefPubMed
10.
go back to reference Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004;64(20):7370–6.CrossRefPubMed Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004;64(20):7370–6.CrossRefPubMed
11.
go back to reference Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 1998;17(2):470–81.CrossRefPubMedPubMedCentral Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 1998;17(2):470–81.CrossRefPubMedPubMedCentral
12.
go back to reference Faragher AJ, Fry AM. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell. 2003;14(7):2876–89.CrossRefPubMedPubMedCentral Faragher AJ, Fry AM. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell. 2003;14(7):2876–89.CrossRefPubMedPubMedCentral
13.
go back to reference Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE. 2008;3(2):e1651.CrossRefPubMedPubMedCentral Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE. 2008;3(2):e1651.CrossRefPubMedPubMedCentral
14.
go back to reference Barbagallo F, Paronetto MP, Franco R, Chieffi P, Dolci S, Fry AM, et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol. 2009;217(3):431–41.CrossRefPubMed Barbagallo F, Paronetto MP, Franco R, Chieffi P, Dolci S, Fry AM, et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol. 2009;217(3):431–41.CrossRefPubMed
15.
go back to reference Andreasson U, Dictor M, Jerkeman M, Berglund M, Sundstrom C, Linderoth J, et al. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am J Hematol. 2009;84(12):803–8.CrossRefPubMed Andreasson U, Dictor M, Jerkeman M, Berglund M, Sundstrom C, Linderoth J, et al. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am J Hematol. 2009;84(12):803–8.CrossRefPubMed
16.
go back to reference Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene. 2010;29(36):5103–12.CrossRefPubMedPubMedCentral Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene. 2010;29(36):5103–12.CrossRefPubMedPubMedCentral
17.
go back to reference Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem. 2002;277(51):49408–16.CrossRefPubMed Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem. 2002;277(51):49408–16.CrossRefPubMed
18.
go back to reference Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res. 2014;42(5):3218–27.CrossRefPubMed Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res. 2014;42(5):3218–27.CrossRefPubMed
19.
go back to reference Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.CrossRefPubMedPubMedCentral Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.CrossRefPubMedPubMedCentral
20.
go back to reference Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8(3):138–40.PubMed Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8(3):138–40.PubMed
21.
go back to reference Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187–94.PubMedPubMedCentral Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187–94.PubMedPubMedCentral
22.
23.
go back to reference Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999;20(1):22–45.CrossRefPubMed Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999;20(1):22–45.CrossRefPubMed
24.
go back to reference Peskoe SB, Joshu CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G et al. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015;75(11):1167–76. Peskoe SB, Joshu CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G et al. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015;75(11):1167–76.
25.
go back to reference Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2015. doi:10.1016/j.eururo.2015.05.009. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2015. doi:10.​1016/​j.​eururo.​2015.​05.​009.
26.
go back to reference Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T. Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process. Prostate. 2015;75(7):748–57.CrossRefPubMed Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T. Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process. Prostate. 2015;75(7):748–57.CrossRefPubMed
27.
go back to reference Hoyer M, Muren LP, Glimelius B. The evolution of radiotherapy techniques in the management of prostate cancer. Acta Oncol. 2015;54(6):821–4.CrossRefPubMed Hoyer M, Muren LP, Glimelius B. The evolution of radiotherapy techniques in the management of prostate cancer. Acta Oncol. 2015;54(6):821–4.CrossRefPubMed
28.
go back to reference Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48–62.CrossRefPubMedPubMedCentral Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48–62.CrossRefPubMedPubMedCentral
29.
go back to reference Matsuhashi A, Ohno T, Kimura M, Hara A, Saio M, Nagano A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012;12(6):625–39.CrossRefPubMed Matsuhashi A, Ohno T, Kimura M, Hara A, Saio M, Nagano A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012;12(6):625–39.CrossRefPubMed
30.
go back to reference Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep. 2014;31(2):745–54.PubMed Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep. 2014;31(2):745–54.PubMed
31.
go back to reference de Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest. 2003;83(2):271–85.CrossRefPubMed de Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest. 2003;83(2):271–85.CrossRefPubMed
32.
go back to reference Cappello P, Blaser H, Gorrini C, Lin DC, Elia AJ, Wakeham A, et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene. 2014;33(18):2375–84.CrossRefPubMed Cappello P, Blaser H, Gorrini C, Lin DC, Elia AJ, Wakeham A, et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene. 2014;33(18):2375–84.CrossRefPubMed
33.
go back to reference Koch M, Wiese M. Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer. J Cancer Res Clin Oncol. 2013;139(2):259–67.CrossRefPubMed Koch M, Wiese M. Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer. J Cancer Res Clin Oncol. 2013;139(2):259–67.CrossRefPubMed
34.
go back to reference Twomey C, Wattam SL, Pillai MR, Rapley J, Baxter JE, Fry AM. Nek2B stimulates zygotic centrosome assembly in Xenopus laevis in a kinase-independent manner. Dev Biol. 2004;265(2):384–98.CrossRefPubMed Twomey C, Wattam SL, Pillai MR, Rapley J, Baxter JE, Fry AM. Nek2B stimulates zygotic centrosome assembly in Xenopus laevis in a kinase-independent manner. Dev Biol. 2004;265(2):384–98.CrossRefPubMed
35.
go back to reference Uto K, Sagata N. Nek2B, a novel maternal form of Nek2 kinase, is essential for the assembly or maintenance of centrosomes in early Xenopus embryos. EMBO J. 2000;19(8):1816–26.CrossRefPubMedPubMedCentral Uto K, Sagata N. Nek2B, a novel maternal form of Nek2 kinase, is essential for the assembly or maintenance of centrosomes in early Xenopus embryos. EMBO J. 2000;19(8):1816–26.CrossRefPubMedPubMedCentral
36.
go back to reference Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triplenegative breast cancer cells. Int J Oncol. 2013;42(3):839–47.PubMedPubMedCentral Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triplenegative breast cancer cells. Int J Oncol. 2013;42(3):839–47.PubMedPubMedCentral
Metadata
Title
Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer
Authors
Yan-Ru Zeng
Zhao-Dong Han
Cong Wang
Chao Cai
Ya-Qiang Huang
Hong-Wei Luo
Ze-Zhen Liu
Yang-Jia Zhuo
Qi-Shan Dai
Hai-Bo Zhao
Yu-Xiang Liang
Wei-De Zhong
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2015
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-015-0085-7

Other articles of this Issue 1/2015

BMC Urology 1/2015 Go to the issue